Society News
-
In Brief for June 25, 2025
The US FDA recently granted approval to taletrectinib for ROS1-positive NSCLC and accepted a priority review for lurbinectedin plus atezolizumab for ES-SCLC in the first-line setting.
-
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting.
-
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery.
-
In Brief for June 11, 2025
VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.
-
Overcoming Resistance Remains a Challenge in Targeting KRAS
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
-
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment.
-
Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs
According to recent phase II data, the experimental treatment demonstrated a median overall survival of 24.5 months.
-
In Brief for May 28, 2025
The US FDA grants accelerated approval to telisotuzumab vedotin-tllv for advanced NSCLC with high c-Met overexpression.
-
In Brief for May 14, 2025
Pembrolizumab-chemotherapy combo receives Canadian approval for first-line treatment of malignant pleural mesothelioma.
-
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going
Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC.
View ILCN Archives
Provider Resources